Multiple Myeloma and Imaging

A special issue of Medicina (ISSN 1648-9144).

Deadline for manuscript submissions: closed (1 May 2021) | Viewed by 4408

Special Issue Editor


E-Mail Website
Guest Editor
Department of Health Sciences, University of Genova, Genova, Italy
Interests: radiology; ultrasound; magnetic resonance imaging; radiomics; breast cancer; oncologic imaging; musculoskeletal imaging; peripheral nervous system
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As you know, bone lesions in multiple myeloma (MM) reduce patients’ quality of life, increasing both morbidity and mortality. Imaging is becoming crucial in the management of patients with MM. Imaging detects not only bone lesions, suggesting immediate start of therapy or follow-up after treatment, but also predicts the risk of early progression from smouldering MM to active disease. In addition, imaging is useful to identify sites of extra-medullary disease and to identify sites of bone disease at potential risk of pathologic fractures or neurologic complications. According to recent staging systems for MM, in patients with new diagnosis, a correct treatment approach and evaluation of prognostic factors also rely on lesion identification in magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography with computerized tomography (PET/CT). Indeed, the role of conventional radiography, the standard of care for many years, is being replaced by more sensitive methods. However, there is still considerable heterogeneity in clinical practice regarding imaging usage in MM, and the updated International Myeloma Working Group (IMWG) criteria now allow for the use of computed tomography (CT), low-dose whole-body CT, and PET-CT in MM. To optimize the use of medical imaging and to take advantage of recent developments in radiomics and AI, this Special Issue highlights the role of medical imaging in MM from standard techniques to more advanced techniques.

Prof. Dr. Alberto Tagliafico
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multiple myeloma
  • computed tomography
  • magnetic resonance imaging
  • positron emission tomography with computerized tomography (PET-CT)
  • radiomics
  • artificial intelligence

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

10 pages, 2146 KiB  
Review
Quantitative Imaging and Radiomics in Multiple Myeloma: A Potential Opportunity?
by Alberto Stefano Tagliafico, Alida Dominietto, Liliana Belgioia, Cristina Campi, Daniela Schenone and Michele Piana
Medicina 2021, 57(2), 94; https://doi.org/10.3390/medicina57020094 - 21 Jan 2021
Cited by 7 | Viewed by 2261
Abstract
Multiple Myeloma (MM) is the second most common type of hematological disease and, although it is rare among patients under 40 years of age, its incidence rises in elderly subjects. MM manifestations are usually identified through hyperCalcemia, Renal failure, Anaemia, and lytic Bone [...] Read more.
Multiple Myeloma (MM) is the second most common type of hematological disease and, although it is rare among patients under 40 years of age, its incidence rises in elderly subjects. MM manifestations are usually identified through hyperCalcemia, Renal failure, Anaemia, and lytic Bone lesions (CRAB). In particular, the extent of the bone disease is negatively related to a decreased quality of life in patients and, in general, bone disease in MM increases both morbidity and mortality. The detection of lytic bone lesions on imaging, especially computerized tomography (CT) and Magnetic Resonance Imaging (MRI), is becoming crucial from the clinical viewpoint to separate asymptomatic from symptomatic MM patients and the detection of focal lytic lesions in these imaging data is becoming relevant even when no clinical symptoms are present. Therefore, radiology is pivotal in the staging and accurate management of patients with MM even in early phases of the disease. In this review, we describe the opportunities offered by quantitative imaging and radiomics in multiple myeloma. At the present time there is still high variability in the choice between various imaging methods to study MM patients and high variability in image interpretation with suboptimal agreement among readers even in tertiary centers. Therefore, the potential of medical imaging for patients affected by MM is still to be completely unveiled. In the coming years, new insights to study MM with medical imaging will derive from artificial intelligence (AI) and radiomics usage in different bone lesions and from the wide implementations of quantitative methods to report CT and MRI. Eventually, medical imaging data can be integrated with the patient’s outcomes with the purpose of finding radiological biomarkers for predicting the prognostic flow and therapeutic response of the disease. Full article
(This article belongs to the Special Issue Multiple Myeloma and Imaging)
Show Figures

Figure 1

7 pages, 299 KiB  
Review
How Can Imaging Help the Radiation Oncologist in Multiple Myeloma Treatment
by Liliana Belgioia, Stefano Vagge, Alberto Tagliafico and Renzo Corvò
Medicina 2021, 57(1), 20; https://doi.org/10.3390/medicina57010020 - 28 Dec 2020
Cited by 4 | Viewed by 1734
Abstract
Multiple myeloma is an incurable malignant tumor of plasma cells of the bone marrow; most patients present a disseminated disease with important bone involvement. Even though a chemotherapy-based approach is the major treatment, radiotherapy often has a supportive role for symptom relief but [...] Read more.
Multiple myeloma is an incurable malignant tumor of plasma cells of the bone marrow; most patients present a disseminated disease with important bone involvement. Even though a chemotherapy-based approach is the major treatment, radiotherapy often has a supportive role for symptom relief but also a radical role for patients with indolent disease or localized forms. In both cases imaging is the basis for treatment planning and for correct patient classification. This paper aims to describe and summarize how radiation oncologists could use imaging information to personalize the treatment for each patient. Full article
(This article belongs to the Special Issue Multiple Myeloma and Imaging)
Back to TopTop